A team at Vanderbilt University Medical Center used machine learning to predict the likelihood of next-day brain function status changes in critical care patients.

Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.

Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7.

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.

Vanderbilt psychiatrists are probing brain circuit hyperactivity implicated in schizophrenia, with the idea that normalizing the hyperactivity may improve cognitive processes.

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.